Evidence map›Paper›PMID 42185453›Full record

ReviewNPJ precision oncology2026

Circulating cell-free methylated DNA immunoprecipitation sequencing (cfMeDIP-seq) in oncology: from technological advances to clinical applications.

Edoardo Francini, Sara Bleve, Giuseppe Nicolo Fanelli, Mara Serena Serafini, Filippo Pederzoli, Alessandra Ferri, Erika Minonne, Jacopo Venturini, Silvia Rodrigues, Hubert Pakula and 3 more

Abstract readReview
In one paragraph

Review in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Edoardo Francini *Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Sara Bleve *Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Giuseppe Nicolo FanelliDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Mara Serena SerafiniDepartment of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USA.
Filippo PederzoliDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.
Alessandra FerriDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.
Erika MinonneDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.
Jacopo VenturiniSarah Cannon Research Institute (SCRI), London, United Kingdom.
Silvia RodriguesDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.
Hubert PakulaDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.
Cristian LolliDepartment of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Massimo CristofanilliDepartment of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USA.
Pier Vitale NuzzoDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA. pvn4001@med.cornell.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circulating cell-free DNA (cfDNA) methylation profiling enables minimally invasive cancer detection and monitoring. Among available methods, cfMeDIP-seq is a sensitive, scalable, bisulfite-free approach suitable for low-input cfDNA. This review summarizes its principles, comparative technologies, and clinical applications, including early detection, tumor classification, and minimal residual disease monitoring. Despite promising performance, challenges remain in standardization and validation, while emerging multi-omic integrations may further enhance its role in precision oncology.

Identifiers

PMID42185453
PMCPMC13478609

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.